CIBC Private Wealth Group
JNCE

CIBC Private Wealth Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

CIBC Private Wealth Group’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-30,000
Closed -$55.5K – 936
2023
Q1 		$55.5K Sell
30,000
-10,425
-26% -$12.9K ﹤0.01% 865
2022
Q4 		$45 Buy
40,425
+20,000
+98% +$28.5K ﹤0.01% 841
2022
Q3 		$48K Buy
+20,425
New +$72.3K ﹤0.01% 890

Other funds holding JNCE

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

CIBC Private Wealth Group's JNCE Position: Q2 2023 in Review

CIBC Private Wealth Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 30,000 shares — an estimated $55.5K sold.

CIBC Private Wealth Group first reported a position in JNCE in Q3 2022 and held it in 3 quarters. The position peaked at $55.5K in Q1 2023. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

  • CIBC Private Wealth Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • CIBC Private Wealth Group sold 30,000 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $55.5K.
  • CIBC Private Wealth Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
  • CIBC Private Wealth Group's Jounce Therapeutics, Inc. Common Stock position peaked at $55.5K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on CIBC Private Wealth Group's 13F filing for Q2 2023, filed 10 Aug 2023.